MapLight Therapeutics' stock plummeted more than 60% this morning after the neuro outfit dropped mix...
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics' stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental...
Author: Fierce Biotech
Read Original Article